Astria Therapeutics' shareholders have seen a 126% increase in share price despite the company's cash burn. With a cash runway of 4.4 years, the company can fund its growth, though an increasing cash burn rate may lead to dilution for shareholders.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing